Mylan N.V. (MYL) Shares are Down -11.57%

Mylan N.V. (MYL) : During the past 4 weeks, traders have been relatively bearish on Mylan N.V. (MYL), hence the stock is down -7.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.99% relative to the S&P 500. The 4-week change in the price of the stock is -8.04% and the stock has fallen -11.57% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 9.75% and the fifty day Moving Average is 6.54%. Mylan N.V. has dropped 0.07% during the last three month period . Year-to-Date the stock performance stands at -20.42%.

Mylan N.V. (MYL) : 6 investment research analysts covering Mylan N.V. (MYL) have an average price target of $59.17 for the near short term. The highest target price given by the Brokerage Firm to the stock is $70 and the lowest target is $52 for the short term. Analysts expect the variance to be within $7.14 of the average price.


Mylan N.V. (NASDAQ:MYL): stock turned positive on Friday. Though the stock opened at $43.11, the bulls momentum made the stock top out at $43.98 level for the day. The stock recorded a low of $42.63 and closed the trading day at $43.03, in the green by 0.42%. The total traded volume for the day was 8,349,591. The stock had closed at $42.85 in the previous days trading.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *